Generic placeholder image

Protein & Peptide Letters


ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Review Article

Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Author(s): Deasmond O. Acheampong*, Christian K. Adokoh*, Paulina Ampomah, Daniel S. Agyirifor, Isaac Dadzie, Francis A. Ackah and Ernest A. Asiamah

Volume 24, Issue 5, 2017

Page: [456 - 465] Pages: 10

DOI: 10.2174/0929866524666170120095128

Price: $65


Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy